Judge in Astellas patent suit denies motion to bolster defendant’s case
A federal judge said drugmakers have “perverted” the intent of Congress when it passed the Hatch-Waxman Act as he declined to supplement his ruling against Astellas in a patent infringement case involving the company’s blockbuster bladder drug.
In 2020 Astellas had sued to stop generic makers from marketing generic versions of an extended-release version of Myrbetriq, its overactive bladder drug. But Judge Joseph Bataillon earlier this month ruled against the Japanese drugmaker.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
